1206195-29-0

Basic information

• Product Name: 4-[5-(4-isopropoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-benzoic acid methyl ester
• Synonyms: 4-[5-(4-isopropoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-benzoic acid methyl ester
• CAS NO: 1206195-29-0
• Molecular Weight: 402.453
• Mol File: 1206195-29-0.mol

Chemical Properties

• CAS DataBase Reference: 4-[5-(4-isopropoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-benzoic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[5-(4-isopropoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-benzoic acid methyl ester(1206195-29-0)
• EPA Substance Registry System: 4-[5-(4-isopropoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino]-benzoic acid methyl ester(1206195-29-0)

Safety Data

• Hazardous Substances Data: 1206195-29-0(Hazardous Substances Data)

Upstream product

• 1206195-27-8 4-(5-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-benzoic acid methyl ester 
• 153624-46-5 4-(isopropoxy)phenylboronic acid 

Downstream Products

• 1206193-93-2 4-(5-(4-isopropoxyphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)benzoic acid 

Relevant articles and documents

NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES.

Novel [l,2,4]triazolo[l,5-a]pyridine compounds are disclosed that have a formula represented by the Formula I. The compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non- limiting example, diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure), diseases involving impairment of cartilage turnover (e.g. diseases involving the anabolic stimulation of chondrocytes), congenital cartilage malformations, diseases associated with hypersecretion of IL6 and transplantation rejection (e.g. organ transplant rejection) and proliferative diseases.